Baidu
map

肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2020 ESMO临床实践指南：前列腺癌的诊断，治疗和随访

2020-06-25 欧洲肿瘤内科学会 Ann Oncol . 2020 Jun 25;

前列腺癌

2020年6月，欧洲肿瘤内科学会(ESMO)发布了前列腺癌的诊断，治疗和随访指南，文是对2015年版指南的更新，主要内涉及前列腺癌的管理建议。

中文标题：

2020 ESMO临床实践指南：前列腺癌的诊断，治疗和随访

英文标题：

Prostate Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

发布机构：

欧洲肿瘤内科学会

发布日期：

2020-06-25

简要介绍：

2020年6月，欧洲肿瘤内科学会(ESMO)发布了前列腺癌的诊断，治疗和随访指南，文是对2015年版指南的更新，主要内涉及前列腺癌的管理建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 ESMO临床实践指南：前列腺癌的诊断，治疗和随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=292311c00193350e, title=2020 ESMO临床实践指南：前列腺癌的诊断，治疗和随访, enTitle=Prostate Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up, guiderFrom=Ann Oncol . 2020 Jun 25;, authorId=0, author=, summary=2020年6月，欧洲肿瘤内科学会(ESMO)发布了前列腺癌的诊断，治疗和随访指南，文是对2015年版指南的更新，主要内涉及前列腺癌的管理建议。, cover=https://img.medsci.cn/2020714/1594658490078_2020535.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Thu Jun 25 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年6月，欧洲肿瘤内科学会(ESMO)发布了前列腺癌的诊断，治疗和随访指南，<span style="color: #373737;">文是对2015年版指南的更新，主要内涉及前列腺癌的管理建议。</span></p> </div> </div> </div>, tagList=[TagDto(tagId=781, tagName=前列腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=781, guiderKeyword=前列腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4745, appHits=288, showAppHits=0, pcHits=1130, showPcHits=4457, likes=0, shares=19, comments=15, approvalStatus=1, publishedTime=Tue Jul 14 01:17:13 CST 2020, publishedTimeString=2020-06-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Jul 14 00:41:39 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 19:56:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ESMO临床实践指南：前列腺癌的诊断，治疗和随访.pdf)])
2020 ESMO临床实践指南：前列腺癌的诊断，治疗和随访.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-11-02 lilili5912

    。。。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-18 唐510

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-15 188200f478m

    很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-02 ms4000002095488795

    很好，学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-02 ms4000002095488795

    很好

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

局部前列腺癌病灶治疗和部分腺体消融术后的标准化命名和监测方法：国际多学科共识 2020

局部治疗协会Focal Therapy Society · 2020-06-14

前列腺癌胚系检测的实施：2019年费城前列腺癌共识

暂未更新 · 2020-06-04

2019 CUA/CUOG指南：转移性单纯去势和去势敏感型前列腺癌

加拿大泌尿外科协会(CUA,Canadian Urological Association) · 2019-12-05

中国前列腺癌患者基因检测专家共识（2019年版）

中国抗癌协会(CACA,Chinese Anti-cancer Association) 泌尿男生殖系肿瘤专业委员会 · 2019-07-30

2019 NICE指南：前列腺癌的诊断和管理（NG.131）

暂未更新 · 2019-05-09

前列腺癌放射治疗安全共识

中国医促会泌尿健康促进分会 · 2019-05-30

拓展阅读

2010 ACS 前列腺癌早期筛查指南

美国癌症学会(ACS,American Cancer Society) · 2010-03-01

2010CCO 前列腺癌根治性前列腺切除术病理T3或边缘阳性的辅助放射治疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-04-15

ESMO临床实践指南：前列腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

2008 前列腺癌骨转移临床诊疗专家共识（2008版）

恶性肿瘤骨转移及骨相关疾病临床诊疗专家组 · 2010-05-01

2011EAU前列腺癌诊疗指南

欧洲泌尿外科学会(EAU,European Association of Urology) · 2011-01-01

前列腺癌诊断标准

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-07-01

Baidu
map
Baidu
map
Baidu
map